Depression impairs learning whereas anticholinergics impair transfer generalization in parkinson patients tested on dopaminergic medications

Cognitive and Behavioral Neurology

Volumn 23, Issue 2, 2010, Pages 98-105

  Herzallah, Mohammad M ^a,b   Moustafa, Ahmed A ^b   Misk, Adel J ^a   Al Dweib, Lara H ^a   Abdelrazeq, Samer A ^a   Myers, Catherine E ^c,d   Gluck, Mark A ^b  

^a AL QUDS UNIVERSITY   (Palestine)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Anticholinergics; Depression in Parkinson disease; Learning and transfer; Parkinson disease

Indexed keywords

AMANTADINE; CARBIDOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; LEVODOPA; PRAMIPEXOLE; DOPAMINE RECEPTOR STIMULATING AGENT; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DEPRESSION; EDUCATION; EMPIRICISM; FEEDBACK SYSTEM; FEMALE; HUMAN; LEARNING; LEARNING DISORDER; LOW DRUG DOSE; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; STIMULUS GENERALIZATION; TEMPORAL LOBE; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE;

AGED; CHOLINERGIC ANTAGONISTS; DEPRESSION; DOPAMINE AGONISTS; FEMALE; HUMANS; LEARNING; MALE; MIDDLE AGED; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; TRANSFER (PSYCHOLOGY); TRIHEXYPHENIDYL;

EID: 77954003116     PISSN: 15433633     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNN.0b013e3181df3048     Document Type: Article

References (59)

1. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988; 318:876-880.
2. Jellinger KA. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol. 1991;14:153-197.
3. Cools R, Barker RA, Sahakian BJ, et al. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex. 2001;11: 1136-1143.
4. Shohamy D, Myers CE, Geghman KD, et al. L-dopa impairs learning, but spares generalization, in Parkinson's disease. Neuropsychologia. 2006;44:774-784.
5. Shohamy D, Myers CE, Kalanithi J, et al. Basal ganglia and dopamine contributions to probabilistic category learning. Neurosci Biobehav Rev. 2008;32:219-236.
6. Moustafa AA, Myers CE, Gluck MA. A neurocomputational model of classical conditioning phenomena: a putative role for the hippocampal region in associative learning. Brain Res. 2009;1276: 180-195.
7. Arnsten AF, Goldman-Rakic PS. Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. Arch Gen Psychiatry. 1998;55:362-368.
8. Zahrt J, Taylor JR, Mathew RG, et al. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci. 1997;17: 8528-8535.
9. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 1995;376: 572-575.
10. Katayama S, Ishizaki F, Yamamura Y, et al. Effects of anticholinergic antiparkinsonian drugs on binding of muscarinic receptor subtypes in rat brain. Res Commun Chem Pathol Pharmacol. 1990;69:261-270.
11. Freedman SB, Beer MS, Harley EA. Muscarinic M1, M2 receptor binding. Relationship with functional efficacy. Eur J Pharmacol. 1988;156:133-142.
12. Levey AI. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci. 1993;52:441-448.
13. Ehrt U, Broich K, Larsen JP, et al. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry. 2010;81:160-165.
14. Pondal M, Del Ser T, Bermejo F. Anticholinergic therapy and dementia in patients with Parkinson's disease. J Neurol. 1996;243: 543-546.
15. Meco G, Casacchia M, Lazzari R, et al. Mental impairment in Parkinson's disease. The role of anticholinergic drugs. Acta Psychiatr Belg. 1984;84:325-335.
16. Myers CE, Ermita BR, Harris K, et al. A computational model of cholinergic disruption of septohippocampal activity in classical eyeblink conditioning. Neurobiol Learn Mem. 1996;66:51-66.
17. Myers CE, Ermita B, Hasselmo M, et al. Further implications of a computational model of septohippocampal cholinergic modulation in eyeblink conditioning. Psychobiology. 1998;26:1-20.
18. Myers CE, Shohamy D, Gluck MA, et al. Dissociating hippocampal versus basal ganglia contributions to learning and transfer. J Cogn Neurosci. 2003;15:185-193. (Pubitemid 36293129)
19. Myers CE, Kluger A, Golomb J, et al. Hippocampal atrophy disrupts transfer generalization in nondemented elderly. J Geriatr Psychiatry Neurol. 2002;15:82-90.
20. Taylor TN, Caudle WM, Shepherd KR, et al. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci. 2009;29:8103-8113.
21. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol. 2008;15(suppl 1):14-20.
22. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson's disease. Parkinsonism Relat Disord. 2007;13(suppl):S2-S7.
23. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5:235-245.
24. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol. 2006;59:591-596.
25. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24: 197-211.
26. Veiga BA, Borges V, Silva SM, et al. Depression in Parkinson's disease: clinical-epidemiological correlates and comparison with a controlled group of non-parkinsonian geriatric patients. Rev Bras Psiquiatr. 2009;31:39-42.
27. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry. 1992;149:443-454.
28. Errea JM, Ara JR. Depression and Parkinson's disease. Rev Neurol. 1999;28:694-698.
29. Bader JP, Hell D. Parkinson's syndrome and depression. Fortschr Neurol Psychiatr. 1998;66:303-312.
30. Walter U, Skoloudik D, Berg D. Transcranial sonography findings related to non-motor features of Parkinson's disease. J Neurol Sci. 2010;289:123-127.
31. Lafer B, Renshaw PF, Sachs GS. Major depression and the basal ganglia. Psychiatr Clin North Am. 1997;20:885-896.
32. Hoeppner J, Prudente-Morrissey L, Herpertz SC, et al. Substantia nigra hyperechogenicity in depressive subjects relates to motor asymmetry and impaired word fluency. Eur Arch Psychiatry Clin Neurosci. 2009;259:92-97.
33. Polgar P, Farkas M, Nagy O, et al. Learning cognitive skills in depression: the effect of context-change. Psychiatr Hung. 2007;22: 271-275.
34. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
35. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
36. Davies AM. Epidemiology of Senile Dementia in Jerusalem, Report of First Phase: Design of a Screening Instrument for Cognitive Dysfunction in the Elderly. Jerusalem: Brookdale Institute of Gerontology, Brookdale Foundation Publications; 1987.
37. Inzelberg R, Schechtman E, Abuful A, et al. Education effects on cognitive function in a healthy aged Arab population. Int Psychogeriatr. 2007;19:593-603.
38. Bowirrat A, Reider G II, Oscar-Berman M, et al. MRI parameters of Alzheimer's disease in an Arab population of Wadi Ara, Israel. Neuropsychiatr Dis Treat. 2005;1:77-85.
39. Friedman A, Friedman Y, Dremencov E, et al. VTA dopamine neuron bursting is altered in an animal model of depression and corrected by desipramine. J Mol Neurosci. 2008;34:201-209.
40. Yadid G, Overstreet DH, Zangen A. Limbic dopaminergic adaptation to a stressful stimulus in a rat model of depression. Brain Res. 2001;896:43-47.
41. Cabib S, Puglisi-Allegra S. Stress, depression and the mesolimbic dopamine system. Psychopharmacology (Berl). 1996;128:331-342.
42. Roth-Deri I, Friedman A, Abraham L, et al. Antidepressant treatment facilitates dopamine release and drug seeking behavior in a genetic animal model of depression. Eur J Neurosci. 2009; 30:485-492.
43. D'Aquila PS, Collu M, Pani L, et al. Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression. Eur J Pharmacol. 1994;262: 107-111.
44. Muscat R, Papp M, Willner P. Antidepressant-like effects of dopamine agonists in an animal model of depression. Biol Psychiatry. 1992;31:937-946.
45. Rodriguez-Oroz MC, Jahanshahi M, Krack P, et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol. 2009;8:1128-1139.
46. Jellinger KA. Post mortem studies in Parkinson's disease-is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl. 1999;56:1-29.
47. Myers CE, Kluger A, Golomb J, et al. Learning and generalization tasks predict short-term cognitive outcome in nondemented elderly. J Geriatr Psychiatry Neurol. 2008;21:93-103.
48. Coutureau E, Killcross AS, Good M, et al. Acquired equivalence and distinctiveness of cues: II. Neural manipulations and their implications. J Exp Psychol Anim Behav Process. 2002;28:388-396.
49. Graux P, Durocher AM, Copin JM. Mental confusion during the treatment of Parkinson's disease with trihexyphenidyl. Lille Med. 1980;25:271-272.
50. Koller WC. Disturbance of recent memory function in parkinsonian patients on anticholinergic therapy. Cortex. 1984;20:307-311.
51. Elvander E, Schott PA, Sandin J, et al. Intraseptal muscarinic ligands and galanin: influence on hippocampal acetylcholine and cognition. Neuroscience. 2004;126:541-557.
52. Kim JS, Levin ED. Nicotinic, muscarinic and dopaminergic actions in the ventral hippocampus and the nucleus accumbens: effects on spatial working memory in rats. Brain Res. 1996;725: 231-240.
53. Hasselmo ME, Wyble BP, Wallenstein GV. Encoding and retrieval of episodic memories: role of cholinergic and GABAergic modulation in the hippocampus. Hippocampus. 1996;6:693-708.
54. Shapovalova KB. Current concepts of the neuromorphology and neurochemistry of the striatal cholinergic system and its role in regulating movement. Zh Vyssh Nerv Deiat Im I P Pavlova. 1996;46:656-673.
55. Di Giovanni G, Shi WX. Effects of scopolamine on dopamine neurons in the substantia nigra: role of the pedunculopontine tegmental nucleus. Synapse. 2009;63:673-680.
56. Maskos U. Emerging concepts: novel integration of in vivo approaches to localize the function of nicotinic receptors. J Neurochem. 2007;100:596-602.
57. Mena-Segovia J, Winn P, Bolam JP. Cholinergic modulation of midbrain dopaminergic systems. Brain Res Rev. 2008;58:265-271.
58. Schmitz Y, Benoit-Marand M, Gonon F, et al. Presynaptic regulation of dopaminergic neurotransmission. J Neurochem. 2003;87:273-289.
59. Simuni T, Sethi K. Nonmotor manifestations of Parkinson's disease. Ann Neurol. 2008;64(suppl 2):S65-S80.